“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it is advantageous compared to other currently available prostate cancer tests. Klotz is a professor of surgery at the University of Toronto, and the chair of prostate cancer research at the Sunnybrook Health Sciences Centre, Ontario, Canada.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.